Physician
Park Pediatrics
Park Pediatrics was paid $12.76M by Medicaid between Jan 2018 and Dec 2024, across 105 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 29% of everything it billed.
33Billing provider infoPARK PEDIATRICS
TAKOMA PARK, MD 20912
TAKOMA PARK, MD 20912
33aNPI1285853135assigned 04/25/2007
33bProvider typePediatrics Physician
28Total paid$12.76M
24GClaims357,550
24DCodes billed105
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pediatrics Physician providers in Maryland
Rank by total paid#5 of 306
Median peer was paid$206K
This provider vs. median62×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,806 | $47K | |
| 2019 | 2,437 | $61K | |
| 2020 | 58,271 | $1.93M | |
| 2021 | 71,153 | $2.49M | |
| 2022 | 85,161 | $2.97M | |
| 2023 | 79,885 | $3.12M | |
| 2024incomplete | 58,837 | $2.14M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 29% | 44,903 | 37,355 | $3.70M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 10% | 13,326 | 12,066 | $1.34M |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 9.5% | 13,394 | 11,106 | $1.22M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 8.1% | 9,237 | 7,813 | $1.03M |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 7.5% | 9,171 | 8,687 | $960K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 4.8% | 5,378 | 5,105 | $618K |
| 90686 | 2.5% | 15,085 | 13,961 | $323K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 2.4% | 7,016 | 6,189 | $312K |
| D1206 | Topical application of fluoride varnish | 2.3% | 12,076 | 11,901 | $297K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 2.1% | 27,633 | 24,818 | $263K |
| 90698 | 1.5% | 9,164 | 8,152 | $190K | |
| 92551 | 1.3% | 18,108 | 16,951 | $166K |
93 more codes
| 90670 | 1.2% | 7,566 | $159K | |
| 99381 | 1.1% | 1,619 | $145K | |
| 90680 | <1% | 5,939 | $123K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 5,790 | $117K |
| 90633 | <1% | 5,023 | $105K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 937 | $103K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 2,624 | $101K |
| 90744 | <1% | 4,629 | $97K | |
| 92587 | <1% | 3,857 | $86K | |
| 90710 | <1% | 3,656 | $78K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 8,874 | $77K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 4,926 | $67K |
| 90651 | <1% | 2,725 | $59K | |
| 99173 | <1% | 21,229 | $52K | |
| 99070 | <1% | 7,981 | $46K | |
| 54150 | <1% | 813 | $43K | |
| 90677 | <1% | 1,491 | $43K | |
| 99460 | <1% | 600 | $43K | |
| 83655 | <1% | 4,688 | $42K | |
| 99383 | <1% | 375 | $42K | |
| 0071A | <1% | 1,050 | $39K | |
| 0072A | <1% | 949 | $37K | |
| 96127 | <1% | 8,194 | $37K | |
| 90696 | <1% | 1,600 | $35K | |
| 90619 | <1% | 1,021 | $34K | |
| 90621 | <1% | 1,480 | $33K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,003 | $32K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 571 | $30K |
| 90715 | <1% | 1,349 | $30K | |
| 99051 | <1% | 4,479 | $29K | |
| 96161 | <1% | 11,995 | $28K | |
| 90734 | <1% | 1,217 | $27K | |
| 0002A | <1% | 679 | $26K | |
| 0001A | <1% | 675 | $26K | |
| 99382 | <1% | 175 | $20K | |
| 99384 | <1% | 142 | $18K | |
| 97802 | <1% | 195 | $18K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 456 | $16K |
| 86580 | <1% | 2,836 | $15K | |
| 90480 | <1% | 438 | $14K | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 451 | $13K |
| 85018 | <1% | 7,098 | $12K | |
| 90380 | <1% | 109 | $12K | |
| 91321 | <1% | 238 | $12K | |
| 90381 | <1% | 96 | $11K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 77 | $10K |
| 0124A | <1% | 352 | $10K | |
| 91320 | <1% | 179 | $10K | |
| 0081A | <1% | 225 | $7K | |
| 90661 | <1% | 334 | $7K | |
| 0003A | <1% | 173 | $6K | |
| 0154A | <1% | 208 | $6K | |
| 0073A | <1% | 147 | $5K | |
| 91319 | <1% | 82 | $4K | |
| 90716 | <1% | 197 | $4K | |
| 90707 | <1% | 193 | $4K | |
| 0111A | <1% | 121 | $4K | |
| 0004A | <1% | 103 | $4K | |
| 91318 | <1% | 58 | $3K | |
| 0082A | <1% | 81 | $3K | |
| 0151A | <1% | 114 | $3K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 292 | $3K |
| 3008F | <1% | 3,655 | $3K | |
| 80061 | Lipid panel | <1% | 241 | $2K |
| 90691 | <1% | 27 | $2K | |
| 99000 | <1% | 8,693 | $2K | |
| 81002 | <1% | 858 | $2K | |
| 0121A | <1% | 51 | $2K | |
| 0112A | <1% | 49 | $1K | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 171 | $1K |
| 92015 | Determination of refractive state | <1% | 38 | $696.10 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 47 | $645.42 |
| 90713 | <1% | 29 | $582.00 | |
| 36416 | <1% | 6,204 | $469.77 | |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | <1% | 81 | $414.80 |
| 94760 | <1% | 204 | $308.52 | |
| 90687 | <1% | 16 | $264.50 | |
| 3011F | <1% | 216 | $201.50 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 108 | $164.39 |
| 91307 | <1% | 1,183 | $133.02 | |
| A7003 | Administration set, with small volume nonfiltered pneumatic nebulizer, disposable | <1% | 33 | $84.13 |
| 81025 | <1% | 13 | $82.28 | |
| A7015 | Aerosol mask, used with dme nebulizer | <1% | 33 | $72.74 |
| 91312 | <1% | 258 | $36.05 | |
| 91308 | <1% | 179 | $36.03 | |
| 91315 | <1% | 317 | $1.95 | |
| 91311 | <1% | 243 | $1.55 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 15 | $1.32 |
| 91317 | <1% | 98 | $0.61 | |
| 91300 | <1% | 943 | $0.59 | |
| 91314 | <1% | 153 | $0.25 | |
| 99402 | 0% | 64 | $0.00 | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 0% | 65 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSADHASIVAM, SITHANANDAM (PEDIATRICIAN)